Royalty Pharma plc Class A Ordinary Shares (RPRX)

FairStock Score: 49/100 — MIXED

Key Financials

Strengths

• Solid return on equity of 13.2% above cost of capital

Concerns

• Trades significantly above Graham Number ($25) with negative 101% margin of safety—limited downside protection

AI Analysis

Royalty Pharma plc Class A Ordinary Shares is a mid-cap healthcare company valued at $29.3 billion. The business generates $2.4 billion in annual revenue with a 9.0% net margin. From a quality standpoint, Royalty shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 2.1 in the grey zone. On valuation, the stock is trading at a premium 27.9x earnings, with trades far above its Graham Number ($25) with no margin of safety. Growth dynamics show revenue growing at 4.8% and profit growth of 2.9%. The 1.9% dividend yield adds an income component for patient holders. Our composite FairStock Score of 43/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Sluggish 5% growth in a large-cap company leaves the stock vulnerable to de-rating if the market rotates toward higher-growth opportunities.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer